TCOT
VIRX

Trust Company of Toledo’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Trust Company of Toledo’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,317
Closed -$1.98K – 246
2024
Q4 		$1.98K Hold
12,317
– – ﹤0.01% 237
2024
Q3 		$2.85K Hold
12,317
– – ﹤0.01% 236
2024
Q2 		$6.7K Hold
12,317
– – ﹤0.01% 232
2024
Q1 		$12.6K Hold
12,317
– – ﹤0.01% 226
2023
Q4 		$7.02K Sell
12,317
-20,896
-63% -$12.8K ﹤0.01% 218
2023
Q3 		$34.5K Sell
33,213
-1,793
-5% -$2.43K 0.01% 210
2023
Q2 		$49.4K Buy
35,006
+7,006
+25% +$10K 0.01% 201
2023
Q1 		$44.5K Buy
+28,000
New +$50.9K 0.01% 199

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Trust Company of Toledo's VIRX Position: Q1 2025 in Review

Trust Company of Toledo sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 12,317 shares — an estimated $1.98K sold.

Trust Company of Toledo first reported a position in VIRX in Q1 2023 and held it in 8 quarters. The position peaked at $49.4K in Q2 2023. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Trust Company of Toledo reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Trust Company of Toledo sold 12,317 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.98K.
  • Trust Company of Toledo first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2023 and held it in 8 quarters.
  • Trust Company of Toledo's Viracta Therapeutics, Inc. Common Stock position peaked at $49.4K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Trust Company of Toledo's 13F filing for Q1 2025, filed 17 Apr 2025.